Clinical Trials Browser

Phase 1/2 × Papillomavirus Infections × 90 days × Clear all

NCT07578467 2026-05-11

Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs

Phase 1/2 Not yet recruiting

Carcinoma, Squamous Cell, Papillomavirus Infections